Published in Eye (Lond) on February 14, 2014
Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema | NCT02979665
Angiogenic potential of vitreous from Proliferative Diabetic Retinopathy and Eales' Disease patients. PLoS One (2014) 0.94
Neuroinflammatory responses in diabetic retinopathy. J Neuroinflammation (2015) 0.91
Comment on 'Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy'. Eye (Lond) (2014) 0.84
Ranibizumab Plus Combined Surgery for Treatment of Neovascular Glaucoma with Vitreous Hemorrhage. Chin Med J (Engl) (2015) 0.83
Anti-VEGF treatment is the key strategy for neovascular glaucoma management in the short term. BMC Ophthalmol (2016) 0.81
Ocular Complications of Diabetes and Therapeutic Approaches. Biomed Res Int (2016) 0.80
Diabetic Retinopathy: Animal Models, Therapies, and Perspectives. J Diabetes Res (2016) 0.79
Identifying Common Genetic Risk Factors of Diabetic Neuropathies. Front Endocrinol (Lausanne) (2015) 0.79
The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol (2016) 0.78
Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment. Eye (Lond) (2016) 0.78
Nanoparticle-mediated miR200-b delivery for the treatment of diabetic retinopathy. J Control Release (2016) 0.76
Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy. Int J Mol Sci (2016) 0.76
A Randomized Controlled Trial of Conbercept Pretreatment before Vitrectomy in Proliferative Diabetic Retinopathy. J Ophthalmol (2016) 0.75
Evaluation of Intravitreal Ranibizumab on the Surgical Outcome for Diabetic Retinopathy With Tractional Retinal Detachment. Medicine (Baltimore) (2016) 0.75
Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine (2015) 0.75
FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice. Cell Rep (2017) 0.75
Visual outcome of laser treatment in diabetic macular edema: Study from an Urban Diabetes Care Center. Pak J Med Sci (2016) 0.75
The significance of the increased expression of phosphorylated MeCP2 in the membranes from patients with proliferative diabetic retinopathy. Sci Rep (2016) 0.75
The effects of pleiotrophin in proliferative diabetic retinopathy. PLoS One (2015) 0.75
DNA Methylomes Reveal Biological Networks Involved in Human Eye Development, Functions and Associated Disorders. Sci Rep (2017) 0.75
Vitrectomy for complications of proliferative diabetic retinopathy in young adults: clinical features and surgical outcomes. Graefes Arch Clin Exp Ophthalmol (2017) 0.75
Novel Genetic Actors of Diabetes-Associated Microvascular Complications: Retinopathy, Kidney Disease and Neuropathy. Rev Diabet Stud (2016) 0.75
Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells. Sci Rep (2017) 0.75
Accelerated degradation of collagen membranes in diabetic rats is associated with increased infiltration of macrophages and blood vessels. Clin Oral Investig (2015) 0.75
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med (1994) 16.24
Pegaptanib for neovascular age-related macular degeneration. N Engl J Med (2004) 12.01
Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology (1991) 5.91
Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology (2006) 4.48
Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA (2010) 4.41
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol (2007) 3.93
Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res (2003) 3.53
Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS One (2008) 3.46
Intravitreal injections: a review of the evidence for best practice. Clin Experiment Ophthalmol (2013) 3.43
Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol (2006) 3.12
Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina (2006) 3.00
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99
Diabetic retinopathy. Diabetes Care (2004) 2.97
Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol (2007) 2.95
Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group. Am J Ophthalmol (1976) 2.70
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (2006) 2.61
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol (2007) 2.51
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology (2005) 2.43
The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology (2011) 2.32
The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology (2011) 2.29
VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J (2006) 2.20
One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology (2012) 2.20
Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res (2000) 2.04
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol (2008) 2.03
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology (2006) 1.80
Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol (2007) 1.71
The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One (2008) 1.68
Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2008) 1.59
Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina (2006) 1.56
Roles for VEGF in the adult. Microvasc Res (2007) 1.48
The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. Retina (2010) 1.47
Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology (2009) 1.46
Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol (2008) 1.45
Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina (2006) 1.45
Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Retina (2010) 1.43
Long-term stability and visual outcome after favorable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology (1991) 1.41
Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology (2009) 1.38
Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology (2009) 1.37
Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye (Lond) (2007) 1.35
Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin (1987) 1.34
Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol (2013) 1.30
Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina (2009) 1.30
Visual loss following panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology (1985) 1.23
Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology (2003) 1.17
Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology (1992) 1.16
Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye (Lond) (2007) 1.13
Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol (2009) 1.13
Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes. Br J Ophthalmol (2007) 1.12
Macular edema following panretinal photocoagulation. Retina (1985) 1.10
Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol (2008) 1.09
Progression of tractional retinal detachment following intravitreal bevacizumab. Acta Ophthalmol (2008) 1.08
Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol (2008) 1.07
Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol (2007) 1.07
Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol (2009) 1.06
Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol (2008) 1.06
A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol (2011) 1.05
Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol (2011) 1.02
Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina (2009) 1.02
Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study). Acta Ophthalmol (2007) 1.00
Macular edema after scatter laser photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol (1980) 1.00
Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol (2008) 0.99
Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina (2009) 0.98
Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Can J Ophthalmol (2009) 0.97
The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol (2005) 0.96
Intravitreal bevacizumab (Avastin) prevention of panretinal photocoagulation-induced complications in patients with severe proliferative diabetic retinopathy. Retina (2008) 0.96
Current therapeutic approaches in neovascular age-related macular degeneration. Discov Med (2013) 0.95
Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev (2011) 0.95
Ischemic maculopathy following intravitreal bevacizumab for refractory diabetic macular edema. Int Ophthalmol (2010) 0.95
Retinal detachment with macular hole following intravitreal bevacizumab in patient with severe proliferative diabetic retinopathy. Br J Ophthalmol (2008) 0.94
Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina (2009) 0.93
Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol (2008) 0.93
Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (avastin) with pars plana vitrectomy. J Ocul Pharmacol Ther (2009) 0.92
Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol (2009) 0.92
Risk factors for ciliochoroidal effusion after panretinal photocoagulation. Ophthalmology (1996) 0.92
Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev (2009) 0.91
Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy. Acta Ophthalmol (2011) 0.90
Systemic adverse events after bevacizumab. Ophthalmology (2009) 0.88
Expression of pigment epithelium-derived factor and vascular endothelial growth factor in fibrovascular membranes from patients with proliferative diabetic retinopathy. Jpn J Ophthalmol (2006) 0.88
Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy. Arch Ophthalmol (2006) 0.85
Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin). Clin Exp Optom (2009) 0.82
Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study): 1-year results. Retina (2013) 0.82
Systemic effects of intravitreal vascular endothelial growth factor inhibitors. Curr Opin Ophthalmol (2013) 0.81
Anti-VEGF therapy in proliferative diabetic retinopathy. Int Ophthalmol Clin (2009) 0.80
Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy. Yonsei Med J (2011) 0.80
Intravitreal pegaptanib in severe proliferative diabetic retinopathy leading to the progression of tractional retinal detachment. Eye (Lond) (2008) 0.80
The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. Indian J Ophthalmol (2007) 0.78
Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib. Acta Ophthalmol (2009) 0.78
Intravitreal bevacizumab for vitreous haemorrhage. Acta Ophthalmol (2007) 0.77
Bevacizumab (Avastin) as a surgical adjunct in diabetic vitrectomy for fibrovascular disease. Eye (Lond) (2008) 0.76
Central corneal thickness and its relationship to the patient's origin. Eye (Lond) (2006) 0.84
Bilateral blurred vision after epidural corticosteroid injection. Intern Med J (2011) 0.75